Showing 7171-7180 of 8607 results for "".
- Senate Unveils Health Care Proposalhttps://practicaldermatology.com/news/senate-unveils-health-care-proposal/2458147/The newly unveiled Senate Republican leadership’s health care proposal, the Better Care Reconciliation Act of 2017, would roll back much of the Affordable Care Act (ACA). According to media reports, the 142-page bill calls for: Elimination of the individual and e
- Stratpharma AG's Wound Care Products Come to the UShttps://practicaldermatology.com/news/stratpharma-ags-wound-care-products-come-to-the-us/2458148/Stratpharma’s wound care and scar management portfolio is now available in the US, according to Stratpharma Inc. USA, a U.S. subsidiary of Stratpharma AG, the Swiss company. The portfolio include
- FDA Approves New Antibiotic for Skin Infectionshttps://practicaldermatology.com/news/fda-approves-new-antibiotic-for-skin-infections/2458149/The FDA has approved Melinta Therapeutics' Baxdela (delafloxacin) for adults for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible bacteria. Baxdela is a fluoroquinolone that exhibits activity against both gram-positive and gram-negative pathog
- Leo Pharma Vet Named New COO for DermaRitehttps://practicaldermatology.com/news/leo-pharma-vet-named-new-coo-for-dermarite/2458157/Barbara J. Osborne is DermaRite Industries’s new Chief Commercial Officer. In her role, Ms. Osborne will be responsible for driving the company's sales and commercialization efforts. She recently served as the U.S. Division President
- And Then There Were Three: Alma Lasers Inc. Hair Removal Platform Now Comprises Three Wavelengthshttps://practicaldermatology.com/news/and-then-there-were-three-alma-lasers-inc-hair-removal-platform-now-comprises-three-wavelengths/2458158/Alma Lasers now offers 1064 Nd: YAG capabilities along with 810nm and 755nm on its Soprano ICE platform, allowing users to better match wavelength to hair removal patient. Alma added Alexandrite technology to its Soprano ICE platform in 2014 for
- EMA Grants Orphan Status to Tarix's EB Candidiatehttps://practicaldermatology.com/news/ema-grants-orphan-status-to-tarixs-eb-candidiate/2458160/The European Medicines Agency (EMA) granted Orphan Drug status to Tarix Orphan LLC’s lead compound, TXA127, for the treatment of epidermolysis bullosa (EB). TXA127 is a pharmaceutical grade formulation of the naturally occurring peptide
- Tildrakizumab Performs Well in Two Phase 3 Psoriasis Studieshttps://practicaldermatology.com/news/tildrakizumab-performs-well-in-two-phase-3-psoriasis-studies/2458164/Two Phase 3 trials show that tildrakizumab is efficacious and well-tolerated in patients with moderate-to-severe chronic plaque psoriasis. Specifically more than 60 percent of all patients who received the active medication showed improvement, compared to less than 10 percent of patients
- Luminora Launches New UPF Sunwear Linehttps://practicaldermatology.com/news/luminora-launches-new-upf-sunwear-line/2458169/Founded by skin cancer surgeon, Dr. Ali Hendi, and his designer wife, Azi Hendi, the Spring/Summer 2017 collection from Luminora launched in May with 12 foundational pieces priced from $60 to $485. Luminora™ is a new
- PFD Patch Improves Laser Tattoo Removal Experiencehttps://practicaldermatology.com/news/pfd-patch-improves-laser-tattoo-removal-experience/2458170/Using a perfluorodecalin (PDF) patch during tattoo removal treatment may make the process quicker, safer and more tolerable, finds a new study in Lasers in Surgery and Medicine (LSM). The study was selected a
- Sun Pharma Announces US FDA Filing Acceptance of Biologics License Application For Tildrakizumabhttps://practicaldermatology.com/news/sun-pharma-announces-us-fda-filing-acceptance-of-biologics-license-application-for-tildrakizumab/2458175/The U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for Sun Pharma’s tildrakizumab, an investigational IL-23p19 inhibitor being evaluated for the treatment of moderate-to-severe plaque psoriasis. The